Komori
E

EIKEN CHEMICAL CO.,LTD.

4549PharmaceuticalsSmall cap
2,411JPY+4.5%
★ Watch (sign-up required)
Price history
¥2,411Latest+27.4%
Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis
Business overview

A corporate group primarily engaged in the manufacture and sale of diagnostic reagents. For the fiscal year ending March 2026, it disclosed revenue of ¥41,899 million, ordinary profit of ¥2,844 million, net income attributable to owners of the parent of ¥3,708 million, total assets of ¥62,657 million, an equity ratio of 70.1%, and 696 employees (364 on average, including temporary employees). The group has formulated a medium- to long-term plan that includes promoting overseas expansion and improving domestic ROIC.

Recurring subjects
No threads yetThis company's filings have not been read yet. We are adding them progressively.
Companies sharing a theme
Loading
Documents
See all timely disclosuresSee all statutory filings
News
See all news
Key numbersShowing 8 of 20
PER
193.04How many years of earnings it would take to buy the stock. The market average is generally considered to be around 15.
PBR
1.97How many times the company's net assets? Around 1x is generally considered a benchmark.
ROE
1.0%Earning power. A figure above 10% is generally considered good.
Dividend yield
0.0%The annual dividend as a percentage of the share price.
Market capitalization
¥86bnShare price × number of shares. The value of the entire company.
Equity ratio
70.1%The proportion of assets funded by money that does not have to be repaid.
Operating margin
6.2%The percentage of revenue remaining from the company’s core business.
Revenue growth (3 years)
2.8%The average annual growth in sales over the past three years.
What to watch next
The ramp-up in immunochemistry supply capacity following completion and the start of production at the Nogi plant’s Immunochemical Product Plant (ICPP) building
From June 2026 onward, pending the quarterly impact on sales and capacity utilizationImpact MediumLikelihood Medium
Progress in overseas adoption and order acquisition following WHO IVD PQ certification and Prequalification of tuberculosis testing kits, including the Loopamp MTBC Detection Kit, in December 2025
FY2026, pending the impact on overseas sales in the next annual or quarterly resultsImpact HighLikelihood Medium
Sales growth following approval and reimbursement coverage for the MINtS Analyzer and MINtS Lung multiplex CDx library preparation reagent kit, marking the launch of the lung-cancer multigene testing line
Fiscal 2026Impact HighLikelihood Medium
Expansion of sales following domestic approval and the launch of Loopamp malaria products for the relevant parasites, including Pf and Pv, in December 2025
Fiscal 2026Impact MediumLikelihood Low
What to watch next
Loading
Who owns itTop holders total 56.8%
Listed holders 56.8%Everyone else 43.2%
The Master Trust Bank of Japan, Ltd. (Trust Account)12.70%
NIPPON ACTIVE VALUE FUND PLC9.92%
AVI JAPAN OPPORTUNITY TRUST PLC6.83%
STATE STREET BANK AND TRUST COMPANY 5051036.64%
THE BANK OF NEW YORK - JASDECTREATY ACCOUNT4.44%
株式会社日本カストディ銀行 (Trust Account)3.84%
NAVF SELECT LLC3.79%
The Dai-ichi Life Insurance Company, Limited3.34%
2 other listed holders5.30%
Who owns it
HolderOwnership (%)
The Master Trust Bank of Japan, Ltd. (Trust Account)12.70
NIPPON ACTIVE VALUE FUND PLC9.92
AVI JAPAN OPPORTUNITY TRUST PLC6.83
STATE STREET BANK AND TRUST COMPANY 5051036.64
THE BANK OF NEW YORK - JASDECTREATY ACCOUNT4.44
株式会社日本カストディ銀行 (Trust Account)3.84
NAVF SELECT LLC3.79
The Dai-ichi Life Insurance Company, Limited3.34
2 other listed holders5.30
This company's documents
Filings
Timely disclosures
Threads